ArticleTargeted oncology2026

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.

Kwon Yong Tak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.